New trends in transplantation: The use of Thymoglobulin®

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 3, 2009, Pages 351-355

  Ballen, Karen ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Immunosuppression; Thymoglobulin ; Transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; AREA UNDER THE CURVE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FEVER; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; LYMPHOMA; MYCOSIS; ORGAN TRANSPLANTATION; REVIEW; SECOND CANCER; SERUM SICKNESS; STEM CELL TRANSPLANTATION; VIRUS INFECTION; ALLOTRANSPLANTATION; ANIMAL; CLINICAL TRIAL; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METHODOLOGY; RABBIT;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; RABBITS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 65549129156     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902755100     Document Type: Review

References (37)

1. Ballen KK, King RJ, Chitphakdithai P, et al. The National Marrow Donor Program Experience: the first 20 years of unrelated donor stem cell transplantation. Biol Blood Marrow Transplant 2008;14:2-7
2. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000;26:397 (Pubitemid 30649555)
3. Ruzek M, Dzuris J, Gao L, et al. Selected mechanistic studies and future directions for thymoglobulin. Transplantation 2007;84:S27-34 (Pubitemid 350294709)
4. Revillard JP. Immunopharmacology of thymoglobulin. Graft 1999;2:S6
5. Brayman K. New insights in to the mechanisms of action of thymoglobulin. Transplantation 2007;84:S3-4 (Pubitemid 350294705)
6. Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003;75:657 (Pubitemid 36337364)
7. Chappell D, Beiras-Fernandez A, Hammer C, et al. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation 2006;81:552-558
8. Beiras-Fernandez A, Thein E, Chappel D, et al. Polyclonal anti-thymocyte globulins influence apoptosis in reperfused tissues after ischemia in a non-human primate model. Transpl Int 2004;17:453-457 (Pubitemid 39362574)
9. Zand MS, Vo T, Pellegrin T, et al. Apoptosis and complement mediated lysis of myeloma cells by polyclonal rabbit anti-thymocyte globulin. Blood 2006;107:2895
10. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;17:2844
11. Lowsky R. Thymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation. Transplantation 2007;84:S20-6
12. Waller EK, Langston AA, Lonial S, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003;9:460-471 (Pubitemid 38351804)
13. Hale GA, Call SK, Handgretinger R, et al. Rabbit anti-thymocyte globlulin pharmacokinetics in pediatric patients receiving a hematopoietic stem cell transplant [abstract]. Biol Blood Marrow Transplant 2006;12, 503 a (abstract)
14. Seidel MG, Fritsch G, Matthes-Martin S, et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005;27:532-536 (Pubitemid 41541069)
15. Regan JF, Lyonnais C, Campbell K, et al. Total and active thymoglobulin levels: effect of dose and sensitization on serum concentration. Transpl Immunol 2001;9:29-36 (Pubitemid 32951933)
16. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003;76:798-802 (Pubitemid 37140222)
17. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990;322:1175-1182 (Pubitemid 20137848)
18. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004;78:136-141 (Pubitemid 38938297)
19. Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation 2006;81:1285-1289 (Pubitemid 43804548)
20. Agha IA, Irfan A, Rueda J, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002;73:473-475 (Pubitemid 34174301)
21. Patel SJ, Duhart BT, Krauss AG, et al. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction. Transplantation 2008;86:313-320
22. Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus ATGam for induction immunosuppressive therapy: 10-year results. Transplantation 2008;86:947-952
23. Mehrabi A, Mood ZA, Sadeghi M, et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant 2007;22(Suppl 8):54-60
24. Soliman T, Hetz H, Burghuber C, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007;13:1039-1064 (Pubitemid 47189018)
25. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with thymoglobulin or campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005;130:528-537 (Pubitemid 41074188)
26. Tanchanco R, Krishnamurthi V, Winans C, et al. Beneficial outcomes of a steroid-free regimen with thymoglobulin induction in pancreas-kidney transplantation. Transplant Proc 2008;40:1551-1556 (Pubitemid 351853133)
27. Nozynski J, Zakliczynski M, Zembala-Nozynska E, et al. Thymoglobulin administered early after heart transplantation reduces early myocardial hypertrophy assessed by morphometric studies. Transplant Proc 2007;39:2825-2832 (Pubitemid 350088102)
28. Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005;35:1011-1018 (Pubitemid 40711839)
29. Duggan P, Booth K, Chaudhry A, et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002;30:681-686 (Pubitemid 35446650)
30. Bacigalupo A, Camparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft versus host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006;12:560-565 (Pubitemid 43956361)
31. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft versus host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006;12:573-578 (Pubitemid 43956362)
32. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007;13:82-89 (Pubitemid 46044092)
33. Ciesca P, Dirlando M, Park SI, et al. Thymoglobulin and rate of infectious complications after transplantation. Transplant Proc 2007;39:463-464 (Pubitemid 46386245)
34. Ballen KK, Cutler C, Yeap BY, et al. High rate of second malignancies after reduced intensity double cord blood transplants in adults [abstract]. Blood 2008;112:1958a
35. Nash RA, Dansey R, Storek J, et al. Epstein-Barr virus associated posttransplantation lymphoproliferative disorders after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003;9:583-591 (Pubitemid 38351790)
36. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of thymoglobulin versus ATGam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67:1011 (Pubitemid 29200852)
37. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003;102:1915-1919 (Pubitemid 37022593)